BeiGene, Ltd. (ONC)

BeiGene, Ltd. (ONC) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $43B; returns 1 day -1.2%, 1 week +2.3%, 1 year +21.8%.

BeOne Medicines Ltd. (formerly BeiGene) is a global, commercial-stage biotechnology leader specializing in the discovery and development of innovative oncology treatments. The company's revenue model is anchored by its flagship product, BRUKINSA (zanubrutinib), a best-in-class BTK inhibitor that accounts for over 60% of total revenue and recently surpassed $1 billion in quarterly sales.

Groups ONC belongs to

• Oncology
• Biotechnology
• Commercial Stage Biotech
• Healthcare
• Commercial Stage
• Hematology
• Hematologic Malignancies
• Pharmaceuticals
• Biopharmaceutical

ONC financial model: income statement, cash flow and balance sheet